David P. Nowotnik

Direktor/Vorstandsmitglied bei TheraTarget, Inc.

75 Jahre

Health Technology

Consumer Services

Aktive Positionen von David P. Nowotnik

Unternehmen	Position	Beginn	Ende
TheraTarget, Inc. TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT.	Direktor/Vorstandsmitglied	-	-

Unternehmen	Position	Beginn	Ende
Guilford Pharmaceuticals, Inc. Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury	Corporate Officer/Principal	01.01.1994	01.01.1998
ABEONA THERAPEUTICS INC.	Corporate Officer/Principal	01.11.1998	-

University of London

Doctorate Degree

International

Vereinigte Staaten	4
Vereinigtes Königreich	2

Operativ

Corporate Officer/Principal	2
Doctorate Degree	1
Director/Board Member	1

Sektoral

Health Technology	4
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
ABEONA THERAPEUTICS INC.	Health Technology

Private Unternehmen	2
Guilford Pharmaceuticals, Inc. Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury	Health Technology
TheraTarget, Inc. TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT.	Health Technology

Private Unternehmen

Health Technology